Though not a huge surprise, the complete response letter (CRL) from the FDA for Lemtrada (alemtuzumab) sent a rumble through the multiple sclerosis (MS) therapy space, and shook investors in Genzyme Corp., which has been told by the agency that approval of the CD52-targeting antibody requires more trials.